Interestingly, while each of the lung, melanoma and breast cancer persister cell types we analyzed here are deficient in one or more anti-ferroptotic factors including NRF2, GSH or in anti-ferroptotic enzymes GPX4, DHODH or VKORC1L1, all were deficient in FSP1. This evidence concerns the gene GPX4 and breast carcinoma.